Arrayed Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Screening Market Report 2026

The arrayed clustered regularly interspaced short palindromic repeats (crispr) screening market size has grown rapidly in recent years. It will grow from $1.52 billion in 2025 to $1.79 billion in 2026 at a compound annual growth rate (CAGR) of 17.5%. The growth in the historic period can be attributed to expansion of functional genomics research, availability of crispr editing reagents, growth of academic screening programs, early adoption of arrayed screening formats, increasing use of cell-based assays.

The arrayed clustered regularly interspaced short palindromic repeats (crispr) screening market size is expected to see rapid growth in the next few years. It will grow to $3.43 billion in 2030 at a compound annual growth rate (CAGR) of 17.7%. The growth in the forecast period can be attributed to increasing demand for precision drug discovery, rising investments in gene therapy research, expansion of disease modeling applications, growing use of bioinformatics-driven screening, increasing collaboration between academia and industry. Major trends in the forecast period include increasing demand for targeted gene validation screens, rising use of high-throughput arrayed crispr assays, growing integration of phenotypic data analytics, expansion of custom crispr screening services, enhanced focus on functional genomics accuracy.

The increasing focus on personalized medicine is anticipated to drive the growth of the arrayed clustered regularly interspaced short palindromic repeats (CRISPR) screening market in the coming years. Personalized medicine refers to a medical approach that tailors treatment and prevention strategies based on an individual’s genetic, biological, and lifestyle characteristics. The adoption of personalized medicine is rising due to advances in genomics and molecular diagnostics, which enable treatments to be customized according to an individual’s genetic profile for improved outcomes. Arrayed CRISPR screening supports personalized medicine by systematically evaluating the impact of specific gene edits on individual cell responses, allowing for the identification of patient-specific drug targets, prediction of treatment responses, and design of therapies tailored to a person’s genetic and cellular profile. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the increasing focus on personalized medicine is driving the growth of the arrayed clustered regularly interspaced short palindromic repeats (CRISPR) screening market.

The rising incidence of genetic diseases is anticipated to drive the growth of the arrayed CRISPR screening market in the coming years. Genetic diseases refer to disorders caused by abnormalities or mutations in an individual’s genes or chromosomes that disrupt normal bodily functions. The prevalence of genetic diseases is increasing due to advanced parental age, which elevates the risk of mutations and chromosomal abnormalities in offspring. Arrayed CRISPR screening supports genetic disease research by evaluating specific genes individually to identify those responsible for disease and enables the development of targeted therapies. For example, in October 2024, according to the Cystic Fibrosis Trust, a UK-based charity dedicated to supporting people with cystic fibrosis, approximately 11,148 cystic fibrosis (a genetic disorder) patients were registered in 2022, and this number rose to 11,318 in 2023, reflecting a 1.5% year-over-year increase in patient registrations. Therefore, the rising incidence of genetic diseases is driving the growth of the arrayed CRISPR screening market.

Companies operating in the arrayed clustered regularly interspaced short palindromic repeats (CRISPR) screening market are focusing on adopting strategic partnerships to enhance high-throughput phenotypic screening precision. A strategic partnership is a formal collaboration in which organizations combine resources, knowledge, or technologies to achieve shared objectives that support quicker innovation, reduced risk, and broader market reach without requiring a merger or acquisition. For example, in November 2023, AstraZeneca Plc, a UK-based science-led biopharmaceutical company, partnered with the Medical Research Council (MRC), a UK-based government agency, and the Milner Therapeutics Institute (MTI) at the University of Cambridge, a UK-based biomedical research institute, to launch a Functional Genomics Screening Laboratory (FGSL), a state-of-the-art facility advancing drug discovery. Its purpose is to map gene-phenotype links in chronic conditions such as cardiovascular and metabolic disorders, advancing UK genomics leadership via open academic collaborations. Advantages include high-throughput automation for precise imaging and phenotyping in organoids or iPSCs, outperforming pooled methods; benefits encompass free access for researchers, faster target validation, and shared expertise to expedite therapies.

Major companies operating in the arrayed clustered regularly interspaced short palindromic repeats (crispr) screening market are Thermo Fisher Scientific Inc, Merck KGaA, GE HealthCare Technologies Inc, Applied Biological Materials Inc, Agilent Technologies Inc, Charles River Laboratories International Inc, Integrated DNA Technologies Inc, GenScript Biotech Corporation, Synthego Holdings LLC, Santa Cruz Biotechnology Inc, Creative Biolabs Inc, VectorBuilder Inc, Admera Health LLC, Addgene Inc, Ncardia, BioCat GmbH, Cellecta Inc, GeneCopoeia Inc, Creative Biogene Inc, and Aelian Biotechnology.

Tariffs are impacting the arrayed CRISPR screening market by increasing costs of imported reagents, enzymes, laboratory instruments, and automated screening systems. Research institutions and biotechnology firms in North America and Europe are most affected due to reliance on specialized imported consumables, while Asia-Pacific faces higher equipment procurement costs. These tariffs are increasing project budgets and extending research timelines. However, they are also supporting local reagent manufacturing, regional instrument assembly, and development of cost-efficient screening platforms.

The arrayed clustered regularly interspaced short palindromic repeats (crispr) screening market research report is one of a series of new reports that provides arrayed clustered regularly interspaced short palindromic repeats (crispr) screening market statistics, including arrayed clustered regularly interspaced short palindromic repeats (crispr) screening industry global market size, regional shares, competitors with a arrayed clustered regularly interspaced short palindromic repeats (crispr) screening market share, detailed arrayed clustered regularly interspaced short palindromic repeats (crispr) screening market segments, market trends and opportunities, and any further data you may need to thrive in the arrayed clustered regularly interspaced short palindromic repeats (crispr) screening industry. This arrayed clustered regularly interspaced short palindromic repeats (crispr) screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Arrayed clustered regularly interspaced short palindromic repeats (CRISPR) screening is a functional genomics method in which specific genes are individually edited or regulated within distinct, well-characterized cell populations using CRISPR-based genome editing tools. This technique allows accurate evaluation of gene roles, phenotypic responses, and biological pathways by clearly linking observed cellular changes to defined genetic modifications.

The primary product types of arrayed clustered regularly interspaced short palindromic repeats (CRISPR) screening products include clustered regularly interspaced short palindromic repeats (CRISPR) libraries, reagents and consumables, instruments, and software and services. Clustered regularly interspaced short palindromic repeats (CRISPR) libraries refer to collections of guide ribonucleic acids designed to target and edit specific genes for high-throughput functional screening. These products are applied across areas such as functional genomics, drug discovery, disease modeling, gene validation, and other applications, and are used by end users including pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations, and other end users.

The arrayed clustered regularly interspaced short palindromic repeats (CRISPR) screening market includes revenues earned by entities through custom arrayed clustered regularly interspaced short palindromic repeats screening services, target gene validation services, functional genomics screening services, assay development services, phenotypic data analysis services, bioinformatics and data interpretation services and genome editing experimental design services, and cell line engineering services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.